DrugInfoSys

Ciprofibrate

Drug #1441

Ciprofibrate is an oral lipid regulating, a fibric acid derivative with actions and uses similar to those of bezafibrate. Ciprofibrate is used in the treatment of type II a, II b, type III , and type IV hyperlipidemias.

← Previous drugNext drug →

Primary Characteristics

It is of Synthetic origin and belongs to Propanoic Acid.

Molecular Weight: 289.2 · pKa: 4.6 · Solubility in Alcohol: highly · Non-proprietary name: Ciprofibrate.

Molecular structure of Ciprofibrate

Pharmacokinetics

Absorption: Ciprofibrate has an oral bioavailability is 49.5% (±49.5%).

Distribution: Ciprofibrate has a volume of distribution is 11.7 litre. plasma protein binding is 95%.

Elimination: plasma half-life is 27-88 hr, renal excretion is 80.2 ± 2.9 %.

Advertisement

Indications

Ciprofibrate is primarily indicated in conditions like Hypercholesterolaemia, Hyperlipidaemias of type IIa, IIb, III and IV in patients who have not responded adequately to diet., Hyperlipidemia, Hypertriglyceridaemia.

Contraindications

Ciprofibrate is contraindicated in conditions like Renal impairment, Hepatic impairment.

Dosage

Ciprofibrate's dosage details are as follows:

DoseSingle DoseFrequencyRouteInstructions
Adult Dosage
100 mg100 mgEvery 24hPO
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown3 interactions
1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Ciprofibrate produces potentially life-threatening effects which include Rhabdomyolysis , Myositis. Careful monitoring is needed with proper medical management.

Ciprofibrate is known to cause more or less tolerable side effects which are usually transient. These include Diarrhea, Drowsiness, Hair loss, Headache, Impotence, Increased intracranial pressure, Nausea, Skin rashes, Tiredness , Vertigo, Vomiting .

Warnings / Precautions

Clofibrate should not be given to patients with severe liver or kidney impairment, primary biliary cirrhosis, gallstone or gallbladder disorder or hypoalbuminaemic state.

Interference in Pathology

Ciprofibrate may interfere in the diagnosis of Liver Function Test (LFT) .

Available Brands

None recorded.

Storage Conditions

Ciprofibrate should be stored Tab.

Drug Classification

  1. 1.12.6 — Lipid-regulating drugs /Anti-atheromas